Close Menu

NEW YORK (GenomeWeb News) – Adaptive Biotechnologies today said that it has received a $2.53 million Phase II Small Business Innovation Research grant to support its adaptive immune system testing technology.

The Seattle-based firm said that it will use the funds, provided by the National Heart, Lung, and Blood Institute, to help commercialize a test that measures the ability of a cancer patient's adaptive immune system to fight infection after a cord blood transplant. Adaptive's test is based on its immunoSEQ next-generation sequencing platform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Noel Rose, the "father of autoimmunity," has died at 92, the Washington Post reports.